- Home
- MRNA vs BMRN Comparison
MRNA vs BMRN Comparison
Compare MRNA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- BMRN
- Stock Information
- Founded
- MRNA 2010
- BMRN 1996
- Country
- MRNA United States
- BMRN United States
- Employees
- MRNA N/A
- BMRN 3040
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MRNA Health Care
- BMRN Health Care
- Exchange
- MRNA Nasdaq
- BMRN Nasdaq
- Market Cap
- MRNA 9.2B
- BMRN 9.9B
- IPO Year
- MRNA 2018
- BMRN 1999
- Fundamental
- Price
- MRNA $24.45
- BMRN $51.46
- Analyst Decision
- MRNA Hold
- BMRN Buy
- Analyst Count
- MRNA 15
- BMRN 19
- Target Price
- MRNA $36.69
- BMRN $90.26
- AVG Volume (30 Days)
- MRNA 11.9M
- BMRN 2.9M
- Earning Date
- MRNA 11-06-2025
- BMRN 10-27-2025
- Dividend Yield
- MRNA N/A
- BMRN N/A
- EPS Growth
- MRNA N/A
- BMRN 59.53
- EPS
- MRNA N/A
- BMRN 2.68
- Revenue
- MRNA $2,232,000,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- MRNA N/A
- BMRN $13.32
- Revenue Next Year
- MRNA $10.38
- BMRN $7.51
- P/E Ratio
- MRNA N/A
- BMRN $19.20
- Revenue Growth
- MRNA N/A
- BMRN 12.39
- 52 Week Low
- MRNA $23.04
- BMRN $50.76
- 52 Week High
- MRNA $56.70
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- MRNA 43.32
- BMRN 40.53
- Support Level
- MRNA $23.48
- BMRN $51.80
- Resistance Level
- MRNA $25.56
- BMRN $53.49
- Average True Range (ATR)
- MRNA 1.46
- BMRN 1.84
- MACD
- MRNA -0.32
- BMRN -0.08
- Stochastic Oscillator
- MRNA 15.89
- BMRN 12.58
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.